Article

Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority Trial

Faculdade de Medicina de Jundiaí, Homeopathy Graduation Programme, Department of Psychobiology, Universidade Federal de São Paulo, R. Napoleão de Barros, 925 São Paulo, SP 04024-002, Brazil.
Evidence-based Complementary and Alternative Medicine (Impact Factor: 1.88). 08/2009; 2011(1741-427X):520182. DOI: 10.1093/ecam/nep114
Source: PubMed

ABSTRACT Homeopathy is a complementary and integrative medicine used in depression, The aim of this study is to investigate the non-inferiority and tolerability of individualized homeopathic medicines [Quinquagintamillesmial (Q-potencies)] in acute depression, using fluoxetine as active control. Ninety-one outpatients with moderate to severe depression were assigned to receive an individualized homeopathic medicine or fluoxetine 20 mg day(-1) (up to 40 mg day(-1)) in a prospective, randomized, double-blind double-dummy 8-week, single-center trial. Primary efficacy measure was the analysis of the mean change in the Montgomery & Åsberg Depression Rating Scale (MADRS) depression scores, using a non-inferiority test with margin of 1.45. Secondary efficacy outcomes were response and remission rates. Tolerability was assessed with the side effect rating scale of the Scandinavian Society of Psychopharmacology. Mean MADRS scores differences were not significant at the 4th (P = .654) and 8th weeks (P = .965) of treatment. Non-inferiority of homeopathy was indicated because the upper limit of the confidence interval (CI) for mean difference in MADRS change was less than the non-inferiority margin: mean differences (homeopathy-fluoxetine) were -3.04 (95% CI -6.95, 0.86) and -2.4 (95% CI -6.05, 0.77) at 4th and 8th week, respectively. There were no significant differences between the percentages of response or remission rates in both groups. Tolerability: there were no significant differences between the side effects rates, although a higher percentage of patients treated with fluoxetine reported troublesome side effects and there was a trend toward greater treatment interruption for adverse effects in the fluoxetine group. This study illustrates the feasibility of randomized controlled double-blind trials of homeopathy in depression and indicates the non-inferiority of individualized homeopathic Q-potencies as compared to fluoxetine in acute treatment of outpatients with moderate to severe depression.

Download full-text

Full-text

Available from: Helena Maria Calil, Aug 15, 2015
0 Followers
 · 
136 Views
  • Source
    • "The products of homeopathy, a complementary and alternative medicine, are produced by dinamization, a process that involves sequentially stirred dilutions in small volumes applied to human and animal diets (Adler et al., 2011). The use of population homeopathy reduces stress to animals, especially in intensive systems that are very different from the natural environment, and increases the production potential and survival. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The homeopathic product Homeopatila 100 ® in the diet of Nile tilapia reduces stress during production and improves the well-being of fish. The objective of this study was to develop nuggets of tilapia fed with Homeopatila 100 ® and to assess their quality. Physical, chemical, microbiological and sensory analyses were performed on three formulations with 25, 50 and 75% mechanically separated meat (MSM) for each of the treatments. The nuggets with 75% MSM revealed a higher pH (5.89 ± 0.02), the tissue was softer (1.29 N ± 0.04), and they had a higher lipid value (15.96% ± 0.05). With 50 and 75%, the color (L *) was darker (60.76% ± 0.91 and 60.03% ± 0.78), and there were lower protein amounts (15.54% ± 0.31 and 13.55% ± 0.35). Nuggets had an acceptable value of lipid oxidation (0.672 ± 0.007 mg MDA/kg). The microbiological analyses demonstrated that the product met the requirements of legislation. Nuggets with 25 and 50% MSM were deemed acceptable. There was no difference (p > 0.05) between the control treatment group and the Homeopatila 100 ® group for the analysis undertaken. The results indicated that the use of Homeopatila 100 ® in the diet of the Nile tilapia did not change the physical, chemical, microbiological and sensorial quality characteristics of the nuggets, ensuring consumer acceptability.
    African journal of pharmacy and pharmacology 03/2015; 9(6):182-189. DOI:10.5897/AJPP2014.4173 · 0.84 Impact Factor
  • Source
    • "For instance, classical homeopathy for children suffering from atopic eczema showed comparable results to conventional treatment in usual care [4]. Moreover, randomized controlled double blind trials using the dynamization scale introduced by the 6 th edition (fifty-millesimal or Quinquagintamillesimal dynamization and its products, the Q-potencies) showed that homeopathically individualized Q-potencies were superior to placebo for fibromyalgia [5] or attention deficit hyperactivity disorder in children [6], and not inferior to the antidepressant fluoxetine in a sample of patients with moderate to severe depression [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The question, proposed by the German Central Union of homeopathic Doctors, is the pivotal subject addressed in a series of lectures and discussions being held all over Germany in 2010, to celebrate the bicentenary of homeopathy´s first medical textbook. Hahnemann´s Organon of the Healing Art is the basis for classical homeopathy. Reading its 6th and posthumous edition is part of the education of 90% of the homeopaths, as indicated by a survey carried out at the 60th Homeopathic World Medical Congress (Berlin 2005). This might be odd to conventional doctors, used to read the latest editions of textbooks and journals, but Hahnemann´s therapeutics seems to be ahead of his time, in that classical homeopathy can be at least as effective as current standard pharmacotherapy. For instance, classical homeopathy for children suffering from atopic eczema showed comparable results to conventional treatment in usual care. Moreover, randomized controlled double blind trials using the dynamization scale introduced by the 6th edition (fifty-millesimal or Quinquagintamillesimal dynamization and its products, the Q-potencies) showed that homeopathically individualized Q-potencies were superior to placebo for fibromyalgia or attention deficit hyperactivity disorder in children, and not inferior to the antidepressant fluoxetine in a sample of patients with moderate to severe depression. More studies using the clinical-pharmaceutical protocol of the Organon are of course needed, but so far its use by trained physicians have yield to challenging results, keeping up with what is recommended in most recent clinical textbooks for the treatment of some chronic diseases.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Homeopathy is often sought by patients with depression. In classical homeopathy, the treatment consists of two main elements: the case history and the prescription of an individually selected homeopathic remedy. Previous data suggest that individualized homeopathic Q-potencies were not inferior to the antidepressant fluoxetine in a sample of patients with moderate to severe depression. However, the question remains whether individualized homeopathic Q-potencies and/or the type of the homeopathic case history have a specific therapeutical effect in acute depression as this has not yet been investigated. The study aims to assess the two components of individualized homeopathic treatment for acute depression, i.e., to investigate the specific effect of individualized Q-potencies versus placebo and to investigate the effect of different approaches to the homeopathic case history. A randomized, partially double-blind, placebo-controlled, four-armed trial using a 2 x 2 factorial design with a six-week study duration per patient will be performed. 228 patients diagnosed with major depression (moderate episode) by a psychiatrist will be included. The primary endpoint is the total score on the 17-item Hamilton Depression Rating Scale after six weeks. Secondary end points are: Hamilton Depression Rating Scale total score after two and four weeks; response and remission rates, Beck Depression inventory total score, quality of life and safety at two, four and six weeks. Statistical analyses will be by intention-to-treat. The main endpoint will be analysed by a two-factorial analysis of covariance. Within this model generalized estimation equations will be used to estimate differences between verum and placebo, and between both types of case history. For the first time this study evaluates both the specific effect of homeopathic medicines and of a homeopathic case taking in patients with depression. It is an attempt to deal with the challenges of homeopathic research and the results might be useful information in the current discussion about the evidence on homeopathy ClinicalTrials.gov: NCT01178255.
    Trials 02/2011; 12(1):43. DOI:10.1186/1745-6215-12-43 · 2.12 Impact Factor
Show more